Request Demo
Last update 15 Jul 2026
Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Last update 15 Jul 2026
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms WBP-263 |
Target |
Action inhibitors |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 27145L
The sequence is quoted from: *****
Sequence Code 83181H
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)NCT07677813
Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study
NCT07604987
A Prospective, Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Rituximab, Pirtobrutinib, High-Dose Methotrexate, Dexamethasone, and Thiotepa (R-PMDT) in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
CTR20190424
比较HL03/WBP263与利妥昔单抗联合CHOP化疗药治疗初治弥漫性大B细胞淋巴瘤有效性和安全性的III期临床研究
[Translation] Phase III clinical study comparing the efficacy and safety of HL03/WBP263 and rituximab combined with CHOP chemotherapy in the treatment of newly diagnosed diffuse large B-cell lymphoma
100 Clinical Results associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Translational Medicine associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Patents (Medical) associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
100 Deals associated with Rituximab biosimilar(Hualan Genetic Engineering Co Ltd)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | NDA/BLA | China | 23 Nov 2024 | |
| CD20 positive B-Cell Lymphoma | Phase 1 | China | 19 May 2018 | |
| CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 1 | China | 19 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free